Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2016 (2016), Article ID 9404705, 14 pages
http://dx.doi.org/10.1155/2016/9404705
Research Article

Th17 Cells Exhibit Antitumor Effects in MDS Possibly through Augmenting Functions of CD8+ T Cells

Department of Hematology, The General Hospital of Tianjin Medical University, Tianjin, China

Received 15 April 2016; Accepted 27 June 2016

Academic Editor: Dipayan Rudra

Copyright © 2016 Jing Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Adès, R. Itzykson, and P. Fenaux, “Myelodysplastic syndromes,” The Lancet, vol. 383, no. 9936, pp. 2239–2252, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. C. Fozza and M. Longinotti, “The role of T-cells in the pathogenesis of myelodysplastic syndromes: passengers and drivers,” Leukemia Research, vol. 37, no. 2, pp. 201–203, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. X.-L. Wang, Z.-H. Shao, C. Yao et al., “Study of Th cell subsets in bone marrow of myelodysplastic syndromes patients,” Chinese Journal of Hematology, vol. 26, no. 1, pp. 753–755, 2005. View at Google Scholar
  4. W. Hua-Quan, S. Zong-Hong, W. Li-Min et al., “Study of changes in the number of CD4+CD25+ Treg and Th3 in peripheral blood of myelodysplastic syndromes patients,” Journal of Immunology Research, vol. 29, no. 7, pp. 482–484, 2008. View at Google Scholar
  5. I. Kotsianidis, I. Bouchliou, E. Nakou et al., “Kinetics, function and bone marrow trafficking of CD4+ CD25+FOXP3+ regulatory T cells in myelodysplastic syndromes,” Leukemia, vol. 23, no. 3, pp. 510–518, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. W. Hamdi, H. Ogawara, H. Handa, N. Tsukamoto, Y. Nojima, and H. Murakami, “Clinical significance of regulatory T cells in patients with myelodysplastic syndrome,” European Journal of Haematology, vol. 82, no. 3, pp. 201–207, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Y. Kordasti, W. Ingram, J. Hayden et al., “CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS),” Blood, vol. 110, no. 3, pp. 847–850, 2007. View at Publisher · View at Google Scholar
  8. S. Y. Kordasti, B. Afzali, Z. Lim et al., “IL-17-producing CD4+ T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome,” British Journal of Haematology, vol. 145, no. 1, pp. 64–72, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Murugaiyan and B. Saha, “Protumor vs antitumor functions of IL-17,” The Journal of Immunology, vol. 183, no. 7, pp. 4169–4175, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Muranski and N. P. Restifo, “Does IL-17 promote tumor growth?” Blood, vol. 114, no. 2, pp. 231–232, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Ye, R. S. Livergood, and G. Peng, “The role and regulation of human Th17 cells in tumor immunity,” The American Journal of Pathology, vol. 182, no. 1, pp. 10–20, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. J. W. Vardiman, J. Thiele, D. A. Arber et al., “The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes,” Blood, vol. 114, no. 5, pp. 937–951, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. P. Greenberg, C. Cox, M. M. LeBeau et al., “International scoring system for evaluating prognosis in myelodysplastic syndromes,” Blood, vol. 89, no. 6, pp. 2079–2088, 1997. View at Google Scholar · View at Scopus
  14. I. Kotsianidis, I. Bouchliou, E. Nakou et al., “Kinetics, function and bone marrow trafficking of CD4+ CD25+FOXP3+ regulatory T cells in myelodysplastic syndromes (MDS),” Leukemia, vol. 23, no. 3, pp. 510–518, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Y. Kordasti, W. Ingram, J. Hayden et al., “CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS),” Blood, vol. 110, no. 3, pp. 847–850, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. P. K. Epling-Burnette, F. Bai, J. S. Painter et al., “Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors,” Blood, vol. 109, no. 11, pp. 4816–4824, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Wu, X. Li, C. Chang, S. Ying, Q. He, and Q. Pu, “Deviation of type I and type II T cells and its negative effect on hematopoiesis in myelodysplastic syndrome,” International Journal of Laboratory Hematology, vol. 30, no. 5, pp. 390–399, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. W. Hamdi, H. Ogawara, H. Handa, N. Tsukamoto, and H. Murakami, “Clinical significance of Th1/Th2 ratio in patients with myelodysplastic syndrome,” International Journal of Laboratory Hematology, vol. 31, no. 6, pp. 630–638, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. L.-L. Shao, L. Zhang, Y. Hou et al., “Th22 cells as well as Th17 cells expand differentially in patients with early-stage and late-stage myelodysplastic syndrome,” PLoS ONE, vol. 7, no. 12, Article ID e51339, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. I. Bouchliou, P. Miltiades, E. Nakou et al., “Th17 and Foxp3+ T regulatory cell dynamics and distribution in myelodysplastic syndromes,” Clinical Immunology, vol. 139, no. 3, pp. 350–359, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. I. I. Ivanov, B. S. McKenzie, L. Zhou et al., “The orphan nuclear receptor rorγt directs the differentiation program of proinflammatory IL-17+ T helper cells,” Cell, vol. 126, no. 6, pp. 1121–1133, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. M. J. McGeachy, K. S. Bak-Jensen, Y. Chen et al., “TGF-β and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain TH-17 cell-mediated pathology,” Nature Immunology, vol. 8, no. 12, pp. 1390–1397, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. X. O. Yang, A. D. Panopoulos, R. Nurieva et al., “STAT3 regulates cytokine-mediated generation of inflammatory helper T cells,” The Journal of Biological Chemistry, vol. 282, no. 13, pp. 9358–9363, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. A. N. Mathur, H.-C. Chang, D. G. Zisoulis et al., “Stat3 and Stat4 direct development of IL-17-secreting Th cells,” Journal of Immunology, vol. 178, no. 8, pp. 4901–4907, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Dong, “TH17 cells in development: an updated view of their molecular identity and genetic programming,” Nature Reviews Immunology, vol. 8, no. 5, pp. 337–348, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. C. E. Egwuagu, “STAT3 in CD4+ T helper cell differentiation and inflammatory diseases,” Cytokine, vol. 47, no. 3, pp. 149–156, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Zhou, I. I. Ivanov, R. Spolski et al., “IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways,” Nature Immunology, vol. 8, no. 9, pp. 967–974, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Mihara, M. Hashizume, H. Yoshida, M. Suzuki, and M. Shiina, “IL-6/IL-6 receptor system and its role in physiological and pathological conditions,” Clinical Science, vol. 122, no. 4, pp. 143–159, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. E. Bettelli, Y. Carrier, W. Gao et al., “Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells,” Nature, vol. 441, no. 7090, pp. 235–238, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. W.-X. Liu, Z.-J. Li, X.-L. Niu, Z. Yao, and W.-M. Deng, “The role of T helper 17 cells and other IL-17-producing cells in bone resorption and remodeling,” International Reviews of Immunology, vol. 34, no. 4, pp. 332–347, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. L. Lu, K. Pan, H.-X. Zheng et al., “IL-17A promotes immune cell recruitment in human esophageal cancers and the infiltrating dendritic cells represent a positive prognostic marker for patient survival,” Journal of Immunotherapy, vol. 36, no. 8, pp. 451–458, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. N. Martin-Orozco, P. Muranski, Y. Chung et al., “T helper 17 cells promote cytotoxic T cell activation in tumor immunity,” Immunity, vol. 31, no. 5, pp. 787–798, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. I. Kryczek, S. Wei, W. Szeliga, L. Vatan, and W. Zou, “Endogenous IL-17 contributes to reduced tumor growth and metastasis,” Blood, vol. 114, no. 2, pp. 357–359, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. J. A. Trapani and M. J. Smyth, “Functional significance of the perforin/granzyme cell death pathway,” Nature Reviews Immunology, vol. 2, no. 10, pp. 735–747, 2002. View at Publisher · View at Google Scholar · View at Scopus